Mutation Testing Encouraged for All Ovarian Cancer Patients
All women with ovarian cancer should have the option of genetic testing, regardless of tumor histology, investigators in a retrospective, tissue-based analysis of a randomized trial concluded. Tumors with defects in homologous recombination (HR)-BRCA1/2 or otherwise-had as much as a 9-month advantage in progression-free survival (PFS) and as much as [ Read More ]